

Felipe von Glehn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2876126/publications.pdf>

Version: 2024-02-01

35
papers

1,687
citations

516215

16
h-index

395343

33
g-index

36
all docs

36
docs citations

36
times ranked

3553
citing authors

#	ARTICLE	IF	CITATIONS
1	Anodal transcranial Direct Current Stimulation over the cerebellum and primary motor cortex improves tardive dyskinesia: A pilot study. <i>Brain Stimulation</i> , 2022, 15, 488-490.	0.7	5
2	Implications of lower extremity muscle power and force for walking and fatigability in multiple sclerosis – An exploratory pilot-study. <i>Clinical Biomechanics</i> , 2022, 96, 105668.	0.5	4
3	The impact of physical functions on depressive symptoms in people with multiple sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 44-50.	0.3	2
4	Cannabinoids in Neurology - Position paper from Scientific Departments from Brazilian Academy of Neurology. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 354-369.	0.3	7
5	Decreased Neurofilament L Chain Levels in Cerebrospinal Fluid and Tolerogenic Plasmacytoid Dendritic Cells in Natalizumab-Treated Multiple Sclerosis Patients – Brief Research Report. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 705618.	1.8	3
6	Effects of hippotherapy on postural balance, functional mobility, self-perceived fatigue, and quality of life in people with relapsing-remitting multiple sclerosis: Secondary results of an exploratory clinical trial. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 102948.	0.9	8
7	Clinical variables that help in predicting the presence of autoantibodies in patients with acute encephalitis. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021, 90, 117-122.	0.9	6
8	Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	23
9	Recommendations by the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and the Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) on vaccination in general and specifically against SARS-CoV-2 for patients with demyelinating diseases of the central nervous system. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 1049-1061.	0.3	5
10	Effect of hippotherapy on walking performance and gait parameters in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102203.	0.9	11
11	High proportion of Guillain-Barré syndrome associated with chikungunya in Northeast Brazil. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e833.	3.1	6
12	From Charcot’s descriptions to the current understanding of neuropsychiatric symptoms in multiple sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2019, 77, 521-524.	0.3	1
13	Validation of the Brazilian version of the patient-determined disease steps scale in persons with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 208-214.	0.9	9
14	Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells. <i>Multiple Sclerosis Journal</i> , 2019, 25, 63-71.	1.4	20
15	Cerebellar atrophy in neuromyelitis optica spectrum disease (NMOSD) patients. <i>Revista Dos Trabalhos De Iniciação Científica Da UNICAMP</i> , 2019, , .	0.0	0
16	Correlating serum micRNAs and clinical parameters in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2018, 58, 261-269.	1.0	78
17	Knee flexor strength and balance control impairment may explain declines during prolonged walking in women with mild multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 181-185.	0.9	23
18	Dimethyl fumarate downregulates the immune response through the HCA2/GPR109A pathway: Implications for the treatment of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 46-50.	0.9	20

#	ARTICLE	IF	CITATIONS
19	Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?. <i>Multiple Sclerosis Journal</i> , 2017, 23, 114-118.	1.4	20
20	Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. <i>JAMA Neurology</i> , 2017, 74, 275.	4.5	52
21	Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e267.	3.1	77
22	MRZH reaction increases sensitivity for intrathecal IgG synthesis in IgG Oligoclonal band negative Multiple Sclerosis patients. <i>Journal of Neuroimmunology</i> , 2016, 300, 30-35.	1.1	5
23	Alterations of the human gut microbiome in multiple sclerosis. <i>Nature Communications</i> , 2016, 7, 12015.	5.8	957
24	Structural brain abnormalities are related to retinal nerve fiber layer thinning and disease duration in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1189-1197.	1.4	70
25	Prognostic indicators for long-term disability in multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2013, 324, 29-33.	0.3	42
26	The Suppressive Effect of IL-27 on Encephalitogenic Th17 Cells Induced by Multiwalled Carbon Nanotubes Reduces the Severity of Experimental Autoimmune Encephalomyelitis. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 682-687.	1.9	23
27	Cerebrospinal fluid analysis in the context of CNS demyelinating diseases. <i>Arquivos De Neuro-Psiquiatria</i> , 2013, 71, 685-688.	0.3	10
28	Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1038-1041.	1.4	50
29	Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis. <i>Immunotherapy</i> , 2012, 4, 1053-1061.	1.0	18
30	Impact of electroacupuncture on quality of life for patients with Relapsing-Remitting Multiple Sclerosis under treatment with immunomodulators: A randomized study. <i>BMC Complementary and Alternative Medicine</i> , 2012, 12, 209.	3.7	32
31	Aquaporin-4 Antibodies Are Not Related to HTLV-1 Associated Myelopathy. <i>PLoS ONE</i> , 2012, 7, e39372.	1.1	13
32	Carpal Tunnel Syndrome with Paracoccidioidomycosis. <i>Emerging Infectious Diseases</i> , 2012, 18, 1390-1392.	2.0	2
33	Monthly variation of multiple sclerosis activity in the southern hemisphere: analysis from 996 relapses in Brazil. <i>European Journal of Neurology</i> , 2012, 19, 660-662.	1.7	16
34	Plasmacytoid dendritic cells are increased in cerebrospinal fluid of untreated patients during multiple sclerosis relapse. <i>Journal of Neuroinflammation</i> , 2011, 8, 2.	3.1	56
35	Early onset of natalizumab-related progressive multifocal leukoencephalopathy. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1397-1398.	1.4	8